In patients with TNBC and HER2-positive breast cancer, immune cell infiltration is detectable in up to 75% of patients and particularly dense infiltration in up to 20% of patients, while the number of TILs is low in the luminal subtypes [8, 9]. Here, ERBB2 is linked to breast carcinoma.